Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Repurposing the NRF2 activator dimethyl fumarate as therapy against synucleinopathy in Parkinson's disease.
Neuroprotective effects of recombinant T-cell receptor ligand in autoimmune optic neuritis in HLA-DR2 mice.
Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation.
Axonal conduction and injury in multiple sclerosis: the role of sodium channels.
Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome.
White matter astrocytes in health and disease.
The effect of vitamin a supplementation on biochemical parameters in multiple sclerosis patients.
Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis.
Interleukin 17F Level and Interferon Beta Response in Patients With Multiple Sclerosis.
Long extensive transverse myelitis associated with aquaporin-4 antibody and breast cancer: Favorable response to cancer treatment.
The Brief Repeatable Battery: psychometrics and normative values with age, education and gender corrections in a Serbian population.
Sex-related factors in multiple sclerosis susceptibility and progression.
Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.
Food and Drug Administration Approval Letter for Alemtuzumab
Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.
Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica.
Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients.
Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod.
Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases.
Remyelination therapy goes to trial for multiple sclerosis
Novartis gains approval for Gilenya® as a first-line disease modifying oral therapy for multiple sclerosis in Switzerland and Australia
Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally.
Mycoplasma pneumonia seroposivity in Iranian patients with relapsing-remitting multipl sclerosis: a randomized case-control study.
Recombinant T cell receptor ligands: immunomodulatory, neuroprotective and neuroregenerative effects suggest application as therapy for multiple sclerosis.
Assessment of sphingosine-1-phosphate receptor expression and associated intracellular signaling cascades in primary cells of the human central nervous system.

Pages